drugset
drugset / Trial / NCT06971198

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation

NCT06971198 ↗

Phase 1 Completed 26 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedSequentialSingle-blindTreatment

Summary

To evaluate the safety, tolerability and pharmacokinetic characteristics of HSK39004 dry powder inhalation in healthy subjects.

Timeline

Start
2025-02-10
Primary completion
2025-03-28
Completion
2025-05-06

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK39004 Unknown — Inhaled

Indications

No indication recorded.